| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 0.73 | 108.6% | 35.2% |
| Total Income | 0.73 | 108.6% | 35.2% |
| Expenditure | 1.97 | 9.4% | 42.8% |
| PBT | — | ||
| Net Profit | -1.51 | 30.4% | 79.8% |
| OPM | — | ||
| NPM | — | ||
| EPS | -0.26 | 7.1% | 52.9% |
20/20 BioLabs Reports Q2 2026 Financial Results: Revenue Up 37%, Cancer Test Revenue Reaches Record
18 Aug 2026 · 18 Aug, 1:43 am
Summary
20/20 BioLabs reported strong second quarter 2026 results, with total revenue increasing 36.5% year-over-year to $0.7 million, driven by a 47.1% surge in OneTest™ revenue. Gross profit saw a significant increase of 86.6% to $0.3 million, with gross margin expanding to 41.7%. The company highlighted progress in state-funded firefighter screening programs and a strengthened cash position of $4.5 million after eliminating convertible note debt. Management expressed optimism about the long-term reimbursement strategy and continued revenue growth driven by MCED testing.
Key Highlights
- 1
Total revenue increased 36.5% to $0.7 million for Q2 2026, compared to $0.5 million for Q2 2025, with OneTest™ accounting for 95.3% of total revenue.
- 2
Revenue from the Company’s OneTest™ family of blood tests increased 47.1% to $0.7 million for Q2 2026, compared to $0.5 million for Q2 2025.
- 3
Gross profit increased 86.6% to $0.3 million for Q2 2026, compared to $0.2 million for Q2 2025, while gross margin expanded to 41.7% from 30.5%.
- 4
State-funded firefighter cancer screening programs are expected to generate more than $1.0 million of revenue through the end of 2026.
- 5
Cash and cash equivalents totaled $4.5 million as of June 30, 2026, compared to $1.0 million as of December 31, 2025.
- 6
All convertible note debt was eliminated during the quarter, strengthening the balance sheet.
Management Comments
Jonathan Cohen
The second quarter was the strongest quarter of multi-cancer early detection testing this Company has ever delivered. OneTest™ revenue grew 47% year-over-year to $0.7 million and represented more than 95% of total revenue, which is exactly the mix shift we have been working toward. Just as importantly, that growth came with operating leverage: gross profit increased 87% and gross margin expanded more than 11 percentage points to 41.7%, because our laboratory absorbs incremental testing volume at attractive incremental economics. State-funded firefighter cancer screening continues to validate OneTest™ in a meaningful commercial setting. Programs in Maryland and Vermont are expected to help us surpass 35,000 firefighters tested by year-end, generating valuable real-world evidence while contributing to revenue growth. That growing body of clinical data supports our long-term reimbursement strategy. With a statutory Medicare pathway for FDA-authorized MCED blood tests beginning in 2028, we believe OneTest™ is well positioned to benefit from expanding adoption as we continue advancing toward commercialization.
Alan Bergman
Second quarter results reflected a return to growth, with revenue increasing 36.5% year over year and gross profit increasing 87% as higher OneTest™ volume drove meaningful operating leverage. Operating expenses increased primarily due to one-time Nasdaq listing costs and continued investment in our longevity platform. We also strengthened the balance sheet meaningfully. During the quarter, we strengthened the balance sheet by raising additional Series E preferred capital and eliminating all outstanding convertible note debt. We ended the quarter with $4.5 million in cash and believe we are well positioned to support continued growth in MCED testing. With two state firefighter programs now contributing and a growing commercial pipeline, we expect MCED volume to remain the primary driver of revenue growth through the balance of the year.
Informational and educational content only. Not investment advice.